Lower-Dose Combo Immunotherapy Promising for Advanced Melanoma

Dr Jeffrey S. Weber reviews data from an open-label phase 1/2 trial assessing the efficacy and safety of combination pembrolizumab and reduced-dose ipilimumab in patients with advanced melanoma.

Source: Medscape Oncology - February 22, 2018 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts